DrugPatentWatch Database Preview
Drugs in Development Information for Camptothecin
Email this page to a colleague
» See Plans and PricingWhat is the drug development status for Camptothecin?
Camptothecin is an investigational drug.
There have been 93 clinical trials for Camptothecin.
The most recent clinical trial was a Phase 2 trial, which was initiated on November 1st 1998.
The most common disease conditions in clinical trials are Lung Neoplasms, Small Cell Lung Carcinoma, and Lymphoma. The leading clinical trial sponsors are National Cancer Institute (NCI), Astex Pharmaceuticals, and University of New Mexico.
Summary for Camptothecin
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 5,501 |
| WIPO Patent Applications | 0 |
| Japanese Patent Applications | 93 |
| Clinical Trial Progress | Phase 2 (1998-11-01) |
| Vendors | 81 |
Recent Clinical Trials for Camptothecin
| Title | Sponsor | Phase |
|---|---|---|
| Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers | National Cancer Institute (NCI) | Phase 2 |
| Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers | Southwest Oncology Group | Phase 2 |
| FOLFIRINOX With Digoxin in Patients With Resectable Pancreatic Cancer | National Cancer Institute (NCI) | Phase 2 |
Clinical Trial Summary for Camptothecin
Top disease conditions for Camptothecin
Top clinical trial sponsors for Camptothecin
US Patents for Camptothecin
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
